Delivery Order SPE2DB22D2211-SPE2DB25FRYHS

Award Date 6/3/25
Potential Completion Date 6/4/25
Potential Value $3.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of FERAHEME 510 MG/17 ML VIAL 17ML, a pharmaceutical product, with a ceiling value of $10,254.76 and a completion date of December 12, 2023. The contract is a Firm Fixed Price arrangement and was not set aside for any specific business type. AmerisourceBergen holds a significant...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of FERAHEME 510 MG/17 ML VIAL 17ML. The contract has a ceiling value of $16,136.63 and runs through January 31, 2025. It is a delivery order contract with a firm fixed price pricing type. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $19,272.72 Firm Fixed Price Delivery Order covers the procurement of FERAHEME 510 MG/17 ML VIAL 17ML, a specialty pharmaceutical product. The contract has an ultimate completion date of July 18, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of FERAHEME 510 MG/17 ML VIAL 17ML, a pharmaceutical product, with a ceiling value of $2,760.50 and a period of performance ending on January 30, 2025. The contract is a firm fixed-price delivery order with no set-aside designation, indicating open competition. AmerisourceBergen Drug...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of FERAHEME 510 MG/17 ML VIAL 17ML, a pharmaceutical product, with a ceiling value of $3,472.02 and a period of performance through May 8, 2025. The contract is not set aside for any specific business type. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of FERAHEME 510 MG/17 ML VIAL 17ML. The contract, valued at $7,639.30, was awarded by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the Department of Defense. This is a delivery order contract with a firm fixed price, and the ultimate completion date is June 10, 2024. The contract is not designated as a set-aside....
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of FERAHEME 510 MG/17 ML VIAL 17ML, a medical product, with a ceiling value of $17,575.71 and a period of performance ending on April 1, 2025. This is a firm fixed-price delivery order contract, with no set-aside designation indicated. AmerisourceBergen holds a significant Indefinite...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract has an award value of $3,131.61 and is for the supply of FERAHEME 510 MG/17 ML VIAL 17ML, a pharmaceutical product. The contract is a delivery order with a firm fixed price pricing type and has an ultimate completion date of February 21, 2025. It is not designated as a set-aside contract. AmerisourceBergen holds a significant Indefinite Delivery...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,558.97, is for the supply of FERAHEME 510 MG/17 ML VIAL 17ML, a pharmaceutical product. The contract has an ultimate completion date of March 26, 2025 and is a firm fixed-price contract. No set-aside designation was used for this award. AmerisourceBergen Drug Corp holds a significant...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,177.57 firm fixed-price delivery order is for the supply of FERAHEME 510 MG/17 ML VIAL 17ML, a pharmaceutical product. The contract has an ultimate completion date of April 21, 2023. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
  • SPE2DB22D2211
    Indefinite Delivery Contract
  • SPE2DB22D2211-SPE2DB25FRYHS
    Delivery Order

This is a Firm Fixed Price Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of FERAHEME 510 MG/17 ML VIAL 17ML. The contract has a ceiling value of $3,856.10 and a performance period ending on June 4, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) valued at $999,999,999.00 with DLA Troop Support Medical, which serves as a comprehensive global pharmaceutical support vehicle for military and government healthcare programs through December 2026. This contract is not designated as a set-aside.

Generated 9/2/25, 9:47 AM